{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:07:50Z","timestamp":1784246870005,"version":"3.55.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To test recommended anticoagulation measures as predictors of 180-day venous thromboembolism (VTE) recurrence, we identified all Olmsted County, MN residents with incident VTE over the 14-year period of 1984-1997, and followed each case (N = 1166) forward in time for VTE recurrence. We tested the activated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures of heparin and warfarin anticoagulation as predictors of VTE recurrence while controlling for baseline and time-dependent characteristics using Cox proportional hazards modeling. Overall, 1026 (88%) and 989 (85%) patients received heparin and warfarin, respectively, and 85 (8%) developed VTE recurrence. In multivariable analyses, increasing proportions of time on heparin with an APTT \u2265 0.2 anti-Xa U\/mL and on warfarin with an INR \u2265 2.0 were associated with significant reductions in VTE recurrence, while the hazard with active cancer was significantly increased. Time from VTE onset to heparin start, duration of overlapping heparin and warfarin, and inferior vena cava (IVC) filter placement were not independent predictors of recurrence. At a heparin dose \u2265 30 000 U\/d, the median proportion of time with an APTT \u2265 0.2 anti-Xa U\/mL was 92%, suggesting that routine APTT monitoring and heparin dose adjustment may be unnecessary. In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence.<\/jats:p>","DOI":"10.1182\/blood-2011-05-357343","type":"journal-article","created":{"date-parts":[[2011,9,4]],"date-time":"2011-09-04T00:44:04Z","timestamp":1315097044000},"page":"4992-4999","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study"],"prefix":"10.1182","volume":"118","author":[{"given":"John A.","family":"Heit","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Diseases (Section of Vascular Diseases) and"},{"name":"Division of Hematology (Section of Hematology Research), Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Lahr","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Petterson","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent R.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel A.","family":"Ashrani","sequence":"additional","affiliation":[{"name":"Division of Hematology (Section of Hematology Research), Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"L. Joseph","family":"Melton","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111808444286100_B1","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"issue":"7138","key":"2019111808444286100_B2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial.","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"issue":"21","key":"2019111808444286100_B3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199211193272103","article-title":"Acenocoumarol and heparin compared with acenocoumarol alone in the intial treatment of prozimal-vein thrombosis.","volume":"327","author":"Brandjes","year":"1992","journal-title":"N Engl J Med"},{"key":"2019111808444286100_B4","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed).","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"issue":"9","key":"2019111808444286100_B5","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2019111808444286100_B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin.","volume":"133","author":"Baglin","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111808444286100_B7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based nomogram compared with a \u201cstandard care\u201d nomogram: a randomized controlled trial.","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"issue":"18","key":"2019111808444286100_B8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.","volume":"315","author":"Hull","year":"1986","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111808444286100_B9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/archinte.1996.00440140107010","article-title":"The relationship between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.","volume":"156","author":"Anand","year":"1996","journal-title":"Arch Intern Med"},{"issue":"22","key":"2019111808444286100_B10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.1997.00440430038005","article-title":"Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.","volume":"157","author":"Hull","year":"1997","journal-title":"Arch Intern Med"},{"issue":"17","key":"2019111808444286100_B11","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1001\/archinte.159.17.2029","article-title":"Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.","volume":"159","author":"Anand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"7","key":"2019111808444286100_B12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111808444286100_B13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1992.00400200027006","article-title":"Optimal therapeutic level of heparin therapy in patients with venous thrombosis.","volume":"152","author":"Hull","year":"1992","journal-title":"Arch Intern Med"},{"issue":"8519","key":"2019111808444286100_B14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(86)91431-5","article-title":"Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.","volume":"2","author":"Gallus","year":"1986","journal-title":"Lancet"},{"issue":"18","key":"2019111808444286100_B15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199005033221802","article-title":"Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.","volume":"322","author":"Hull","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808444286100_B16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archinte.158.9.1005","article-title":"Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism.","volume":"158","author":"White","year":"1998","journal-title":"Arch Intern Med"},{"issue":"6","key":"2019111808444286100_B17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"95","key":"2019111808444286100_B18","first-page":"547","article-title":"Monitoring unfractionated heparin with the aPTT: time for a fresh look.","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111808444286100_B19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jvs.2005.05.053","article-title":"Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.","volume":"42","author":"Caprini","year":"2005","journal-title":"J Vasc Surg"},{"issue":"13","key":"2019111808444286100_B20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/archinte.165.13.1458","article-title":"Antithrombotic therapy practices in US hospitals in an era of practice guidelines.","volume":"165","author":"Tapson","year":"2005","journal-title":"Arch Intern Med"},{"key":"2019111808444286100_B21","unstructured":"The Joint Commission\n          Performance measurement initiatives: national consensus standards for prevention and care of venous thromboembolism (VTE).\n          2010\n          \n            http:\/\/www.jointcommission.org\/specifications_mannual_for_national_hospital_inpatient_quality_measures"},{"issue":"15","key":"2019111808444286100_B22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111808444286100_B23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111808444286100_B24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.","volume":"307","author":"Hull","year":"1982","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808444286100_B25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2005.01330.x","article-title":"Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.","volume":"3","author":"Palareti","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111808444286100_B26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4065\/71.3.266","article-title":"History of the Rochester Epidemiology Project.","volume":"71","author":"Melton","year":"1996","journal-title":"Mayo Clinic Proc"},{"issue":"6","key":"2019111808444286100_B27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, cohort study.","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"issue":"8","key":"2019111808444286100_B28","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1538-7836.2005.01415.x","article-title":"Venous thromboembolism: disease burden, outcomes and risk factors. State of the Art.","volume":"3","author":"Heit","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111808444286100_B29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019111808444286100_B30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/ATVBAHA.109.189290","article-title":"Is diabetes mellitus an independent risk factor for venous thromboembolism? a population-based case-control study.","volume":"29","author":"Heit","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2019111808444286100_B31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Fixed-Dose Heparin (FIDO) I. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.","volume":"296","author":"Kearon","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"2019111808444286100_B32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.CIR.12.4.553","article-title":"Studies of intravascular coagulation: IV. The effect of heparin and dicumarol on serum-induced venous thrombosis.","volume":"12","author":"Wessler","year":"1955","journal-title":"Circulation"},{"issue":"2","key":"2019111808444286100_B33","first-page":"320","article-title":"Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin.","volume":"73","author":"Zucker","year":"1969","journal-title":"J Lab Clin Med"},{"issue":"2","key":"2019111808444286100_B34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.V49.2.171.bloodjournal492171","article-title":"Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis.","volume":"49","author":"Chiu","year":"1977","journal-title":"Blood"},{"issue":"3","key":"2019111808444286100_B35","first-page":"463","article-title":"Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants.","volume":"70","author":"Edson","year":"1967","journal-title":"J Lab Clin Med"},{"issue":"3","key":"2019111808444286100_B36","first-page":"191","article-title":"Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.","volume":"41","author":"Cirisano","year":"1996","journal-title":"J Reprod Med"},{"issue":"4","key":"2019111808444286100_B37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.2003.04795.x","article-title":"High plasma levels of factor VIII and risk of recurrence of venous thromboembolism.","volume":"124","author":"Cristina","year":"2004","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111808444286100_B38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198409063111007","article-title":"Warfarin. From bedside to bench.","volume":"311","author":"Wessler","year":"1984","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808444286100_B39","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1172\/JCI116814","article-title":"Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.","volume":"92","author":"Zivelin","year":"1993","journal-title":"J Clin Invest"},{"issue":"13","key":"2019111808444286100_B40","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/archinte.160.13.2033","article-title":"A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism.","volume":"160","author":"White","year":"2000","journal-title":"Arch Intern Med"},{"issue":"2","key":"2019111808444286100_B41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurent venous thromboembolism in patients with cancer.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111808444286100_B42","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch Intern Med"},{"issue":"10","key":"2019111808444286100_B43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2009-04-215418","article-title":"A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families.","volume":"114","author":"Lijfering","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111808444286100_B44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111808444286100_B45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy.","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111808444286100_B46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1538-7836.2008.03224.x","article-title":"Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.","volume":"7","author":"Cuker","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2019111808444286100_B47","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed).","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4992\/1463796\/zh804411004992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4992\/1463796\/zh804411004992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:42:38Z","timestamp":1574088158000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/18\/4992\/29338\/Heparin-and-warfarin-anticoagulation-intensity-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,3]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,11,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-357343","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,3]]}}}